AstraZeneca receives CDSCO approval to launch eculizumab in India
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Investment will fund expansion to meet rising demand for CRDMO services
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Increases speed to market for drug developers working on nucleic acid therapeutics
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Subscribe To Our Newsletter & Stay Updated